BioVenture Consultants

CYNTHIA ROBBINS-ROTH,PH.D

Principal

The founder of BioVenture Publishing Inc. (acquired by PJB Publications 1996) and BioVenture Consultants, Cynthia Robbins-Roth has been part of the biotechnology industry since 1981. A frequent speaker on issues and events affecting the industry, she combines a technical background with extensive experience in the business and finance issues that drive this growing sector.

Dr. Robbins-Roth holds a Ph.D. in Biochemistry from the University of Texas Medical Branch, completed post-doctoral work in its Microbiology Department, and was a research scientist within the Immunology and Protein Biochemistry groups at Genentech, Inc. She then joined the Business Development group at California Biotechnology Inc. (now Scios/J&J).

Dr. Robbins-Roth has been a consultant to the Bioscience Industry since 1986, providing technology assessment, competitor analysis, strategic planning, due diligence, market analysis and fund management consultation services. Her clients have included major venture capital firms, established biotech and pharmaceutical companies, government agencies, and early-stage biotechnology companies. Dr. Robbins-Roth served as a member of the Board of Directors of BioVeda Capital (Singapore), NewBiotics and Asilomar-early-stage biotechnology companies, and serves on the Advisory Boards of New Zealand Trade & Enterprise and Genesys Capital (Toronto).

Dr. Robbins-Roth founded in 1986 BioVenture Publishing, which produced BioVenture View, a monthly newsletter covering key business and product developments, and BIOPEOPLE Magazine, the first biotech industry business magazine. She was the founding Editor-in-Chief (1989 - 1991) of BioWorld Publications, the first daily biotechnology news and information service, and currently writes a column for BioWorld Today.

She is the editor and author of “Alternative Careers in Science: Leaving the Ivory Tower” (Academic Press, 2nd edition 2005) and wrote a biotechnology column for Forbes ASAP Magazine and Biotechnology Investing.com. Her second book, “From Alchemy to IPO: The Business of Biotechnology” (Perseus Press) was published in April 2000 and has been translated into five foreign languages.

Home Contact Us

Other Biotech Links:
Recap   BioWorld   Sedar   Wall Street Journal   Edgar  
BioMedNet  BioSpace  BIO